Search this site

Neurofibromatosis Type 1, Type 2, and Schwannomatosis Q. What is Neurofibromatosis? Neurofibromatosis refers to a group of autosomal dominant neurocutaneous disorders characterized by the formation of nerve sheath tumors, skin pigmentation abnormalities, and systemic manifestations involving multiple organ systems. The three major recognized forms are Neurofibromatosis Type 1 (NF1), Neurofibromatosis Type 2 (NF2), and Schwannomatosis, all part of the neurofibromatosis-schwannomatosis spectrum. Neurofibromatosis Type 1 (NF1) Q. What is the genetic basis of NF1? NF1 results from mutations in the NF1 gene on chromosome 17q11.2, which encodes neurofibromin, a tumor suppressor protein that negatively regulates RAS signaling. Loss of neurofibromin leads to excessive RAS/MAPK pathway activation and uncontrolled Schwann cell proliferation. Q. What is the inheritance pattern? NF1 is autosomal dominant with variable expressivity and complete penetrance by adulthood. Around 50% of cases arise from de novo mutations. Q. What are the updated 2021 International Diagnostic Criteria for Neurofibromatosis Type 1 (NF1)? Diagnosis requires two or more of the following: 1. Six or more café-au-lait macules (>5 mm prepubertal, >15 mm postpubertal). 2. Two or more neurofibromas of any type, or one plexiform neurofibroma. 3. Axillary or inguinal freckling (Crowe sign). 4. Optic pathway glioma. 5. Two or more Lisch nodules (iris hamartomas), OR two or more choroidal abnormalities (bright patch lesions identified by near-infrared reflectance imaging / optical coherence tomography). 6. Distinctive osseous lesion such as sphenoid wing dysplasia, anterolateral bowing of the tibia, or pseudarthrosis of a long bone. 7. A heterozygous pathogenic NF1 gene variant with a variant allele fraction of 50% in normal tissue. 8. A parent who meets the diagnostic criteria for NF1 specified above. (Only a biological parent who officially meets the diagnostic criteria qualifies as a positive family history. Siblings and children no longer satisfy this criterion on their own, even if they have confirmed cases of NF1.) Q. What are the additional supportive (nonessential) features of NF1? Macrocephaly, short stature, and learning disabilities or ADHD. Seizures, developmental delay, or autism spectrum traits. Scoliosis, vertebral scalloping, long bone bowing, and tibial dysplasia. Vascular lesions (e.g., renal artery stenosis, moyamoya-like disease). Endocrine abnormalities, including precocious puberty (optic-hypothalamic glioma). Pheochromocytoma, GISTs, glomus tumors, and juvenile xanthogranulomas. Choroidal hamartomas visible on near-infrared OCT. Elephantiasis neuromatosa from plexiform neurofibroma overgrowth. Q. What are the clinical features of NF1? Cutaneous: café-au-lait macules, axillary/inguinal freckles, dermal and plexiform neurofibromas. Ophthalmic: Lisch nodules, optic pathway glioma. Neurologic: learning disability, ADHD, seizures, headaches. Skeletal: scoliosis, bone dysplasia. Tumors: MPNST, astrocytoma, pheochromocytoma. Q. What are the radiologic findings? MRI brain may show optic pathway glioma and T2 hyperintense white matter lesions (“unidentified bright objects”). Plexiform neurofibromas appear as T2 target sign lesions. Q. How is NF1 managed? Observation for asymptomatic lesions. Surgical excision for symptomatic or disfiguring neurofibromas. Optic gliomas: observe unless progressive visual loss. When treatment is required for progressive vision loss or imaging advancement, chemotherapy (e.g., carboplatin/vincristine or BRAF/MEK inhibitors) is first-line; radiation is strictly avoided due to the high risk of secondary malignancies and moyamoya syndrome. Screening: annual BP, ophthalmology, and neuro exam; MRI only if symptomatic. MPNST suspicion: rapid growth, pain, or heterogeneity on MRI → biopsy. Q. What is the prognosis? Most live normal lifespans; risk of malignant transformation (MPNST) and vascular complications determine prognosis. Neurofibromatosis Type 2 (NF2) Q. What is the genetic basis of NF2? NF2 is caused by mutations in the NF2 gene on chromosome 22q12, encoding merlin (schwannomin), a tumor suppressor that regulates cell–cell contact inhibition. Loss of merlin leads to Schwann cell overgrowth and meningeal proliferation. Q. What is the inheritance pattern? NF2 is autosomal dominant with variable expression and near-complete penetrance by age 60. Around 50% are de novo mutations, and one-third of those are mosaic. Q. What are the diagnostic criteria for NF2-related schwannomatosis (updated 2022)? Diagnosis can be made by: 1. Bilateral vestibular schwannomas, or 2. A first-degree relative with NF2-related schwannomatosis plus either - unilateral vestibular schwannoma, or - any two of: meningioma, schwannoma, glioma, neurofibroma, or juvenile cataract. 3. NF2 pathogenic variant in blood or tumor, with compatible clinical features. Q. What are supportive clinical features of NF2? Bilateral vestibular schwannomas (pathognomonic). Multiple meningiomas (intracranial and spinal). Spinal ependymomas and schwannomas. Ocular: posterior subcapsular cataract, epiretinal membranes, retinal hamartomas. Cutaneous: plaque-like or subcutaneous schwannomas (no café-au-lait spots). Cranial neuropathies and hearing loss as early symptoms. Family history of early-onset hearing loss or CNS tumors. Q. What is the typical age of presentation? Adolescence or early adulthood, though pediatric onset may occur in mosaic NF2. Q. What are the imaging findings? MRI Brain/IAC: bilateral vestibular schwannomas, multiple meningiomas. MRI spine: intradural extramedullary schwannomas, ependymomas, or meningiomas. Q. How is NF2 managed? MRI surveillance (brain and spine every 12–24 months). Microsurgery or radiosurgery for symptomatic tumors. Bevacizumab for progressive vestibular schwannomas to reduce growth and improve hearing. Rehabilitation with cochlear or brainstem implants for hearing loss. Genetic counseling for family. Q. What is the prognosis? Progressive and multisystemic; median life expectancy around 60 years. Morbidity arises from bilateral hearing loss and brainstem compression. Schwannomatosis Q. What is schwannomatosis? Schwannomatosis is a rare tumor predisposition syndrome characterized by multiple non-vestibular schwannomas without bilateral vestibular schwannomas. It is now considered part of the NF2-related schwannomatosis spectrum. Q. What is the genetic basis? Three defined molecular subtypes: 1. NF2-related schwannomatosis – NF2 gene mutation (chromosome 22q12). 2. SMARCB1-related schwannomatosis – SMARCB1 mutation (chromosome 22q11.23). 3. LZTR1-related schwannomatosis – LZTR1 mutation (chromosome 22q11.23). Tumorigenesis follows a four-hit, three-step model: biallelic loss of both NF2 and one modifier gene (SMARCB1 or LZTR1) in the same cell. Q. What is the inheritance pattern? Autosomal dominant with incomplete penetrance and variable expressivity. Many cases are sporadic. Q. What are the diagnostic criteria (2022 update)? Clinical diagnosis: - Two or more non-intradermal schwannomas confirmed histologically. - No bilateral vestibular schwannomas on MRI. - No constitutional NF2 mutation or first-degree relative with NF2. Molecular diagnosis: - Pathogenic variant in SMARCB1, LZTR1, or NF2, in germline or mosaic form, without bilateral vestibular involvement. Q. What are the clinical features? Chronic or paroxysmal pain (hallmark symptom). Palpable nerve masses along peripheral or spinal nerves. No vestibular or hearing symptoms. Minimal skin lesions, no café-au-lait spots or Lisch nodules. May have mononeuropathies or focal weakness due to nerve compression. Q. What are the radiological features? MRI: multiple enhancing schwannomas along peripheral or spinal nerves, no vestibular schwannomas. Diffusion and contrast help differentiate from meningiomas or neurofibromas. Q. What are the histopathological findings? Typical schwannoma pattern: - Antoni A and Antoni B areas. - Verocay bodies in Antoni A. - Strong S-100 positivity. - No entrapped axons (unlike neurofibroma). Q. What are the differences among genetic subtypes? SMARCB1-related: early onset, spinal schwannomas, occasional meningiomas. LZTR1-related: peripheral nerve tumors, occasional unilateral vestibular schwannoma. NF2-related: mosaic or milder NF2 phenotype. Q. How is schwannomatosis managed? Surgical resection of symptomatic schwannomas. Pain control with neuropathic agents and nerve blocks. MRI surveillance every 2–3 years. Genetic counseling for family. No established drug therapy; bevacizumab is ineffective except in NF2-related cases. Q. What is the prognosis? Excellent life expectancy; main morbidity is chronic neuropathic pain and recurrent surgeries. Histologic Discussion: Schwannoma vs Neurofibroma Q. How do schwannoma and neurofibroma differ? Schwannoma: encapsulated, eccentric to nerve, purely Schwann cells, Antoni A/B areas, Verocay bodies, strong S-100, no axons, enucleable, rare malignancy. Neurofibroma: unencapsulated, intraneural, mixed cell types with axons inside, patchy S-100, CD34 positive stroma, “shredded carrot” collagen, plexiform type has MPNST risk. Target sign on MRI typical for neurofibroma; heterogeneous appearance for schwannoma. Q. What are Antoni A and Antoni B areas, and Verocay bodies? Antoni A areas are hypercellular and organized with nuclear palisading. Antoni B areas are hypocellular, myxoid, and loosely arranged. Verocay bodies are rows of palisaded nuclei separated by acellular eosinophilic zones of Schwann cell processes, pathognomonic for schwannoma. Q. What is segmental or mosaic NF? A postzygotic mutation causing localized disease limited to one body segment; germline mosaicism can still transmit generalized NF to offspring. Q. What is plexiform neurofibroma and why is it significant? Pathognomonic of NF1, involving multiple fascicles (“bag of worms”). Carries 10–15% risk of malignant transformation to MPNST. Q. What is MPNST? A high-grade sarcoma arising from plexiform neurofibroma or peripheral nerve sheath, characterized by pain, rapid growth, and heterogeneous MRI appearance. Genetic mechanisms of tumorigenesis: Both NF1 and NF2 follow the two-hit tumor suppressor model; loss of both alleles (somatic and germline) causes tumor formation. NF1: RAS pathway dysregulation. NF2: loss of contact inhibition via merlin deficiency. Follow-up protocols: NF1 – annual BP, neuro and eye exams, MRI if symptomatic. NF2 – MRI brain/IAC annually, spine every 2–3 years, audiology yearly. Schwannomatosis – MRI every 2–3 years, pain and nerve function monitoring. Final recall summary: NF1 = Peripheral + Pigmentary. NF2 = Central + Vestibular. Schwannomatosis = Multiple Painful Schwannomas, No Vestibular Involvement.

Dandy-Walker Malformation Dandy–Walker malformation is a congenital posterior fossa anomaly characterized by: Markedly enlarged posterior cranial fossa, Partial or complete aplasia of the cerebellar vermis, and Cystic dilatation of the fourth ventricle, which expands posteriorly into the enlarged fossa. The posterior fossa is often described as “deformed and wrapped in a neuroglial–vascular membrane.” Hydrocephalus is common. Q. What is the embryological basis of DWM? DWM results from developmental arrest/dysembryogenesis of the anterior membranous area (AMA) of the fetal rhombencephalic roof prior to the 6th–7th week of gestation. This failure of normal development prevents midline fusion of the cerebellar primordia (leading to vermian aplasia/hypoplasia) and causes persistence and cystic ballooning of the fourth ventricle. It is not caused by primary outlet obstruction/atresia of Luschka and Magendie. Q. What associated anomalies may be seen with DWM? DWM coexists with CNS and systemic abnormalities in up to 50–70% of cases: CNS Anomalies: • Corpus callosum agenesis or dysgenesis (17–50%) • Occipital encephalocele (~7%) • Neuronal migration defects (heterotopias, polymicrogyria) • Spinal dysraphism & spinal cord syrinx • Brainstem hypoplasia & microcephaly Systemic Anomalies: • Cardiac malformations (VSD, ASD, Tetralogy of Fallot) • Genitourinary anomalies (polycystic kidneys) • Craniofacial clefts • PHACE syndrome & Klippel–Feil syndrome Q. What conditions fall under the “Dandy–Walker complex”? The “Dandy–Walker Complex” includes the spectrum of posterior fossa cystic malformations: 1. Dandy–Walker malformation (DWM) 2. Dandy–Walker variant (DWV): partial features such as vermian hypoplasia or fourth ventricular cyst without posterior fossa enlargement 3. Blake’s pouch cyst (BPC): communicating 4th ventricle with posterior fossa cyst 4. Retrocerebellar arachnoid cyst: pushes cerebellum and fourth ventricle anteriorly; vermis intact 5. Joubert syndrome: vermian agenesis 6. Mega cisterna magna: enlarged cisterna with normal vermis and fourth ventricle Q. How do you differentiate DWM from other posterior fossa cystic lesions? Key Differentiating Features: • Vermis: – Severe hypoplasia/agenesis with superior/counter-clockwise rotation in DWM. – Intact (or only upwardly displaced) in Blake’s pouch cyst and arachnoid cysts. – Completely normal in mega cisterna magna. – Hypoplastic with "molar tooth" configuration of superior cerebellar peduncles in Joubert syndrome. • Fourth Ventricular Choroid Plexus: – Displaced inferolaterally or absent in the roof in DWM. – Displaced along the cyst wall/inferior to the vermis in Blake’s pouch cyst. – Normal intraventricular position (isolated from the extra-axial cyst) in arachnoid cysts. • Posterior Fossa Size & Torcula Position: – Enlarged with elevated tentorium/torcula above the lambdoid suture ("torcular-lambdoid inversion") in DWM. – Normal volume and normal torcula position in Blake’s pouch cyst, Joubert syndrome, and mega cisterna magna. • Subarachnoid Communication: – Mega cisterna magna communicates freely with CSF pathways. – DWM and retrocerebellar arachnoid cysts generally do not communicate freely with the main subarachnoid spaces. Q. What are the clinical features of Dandy–Walker malformation? Features result from hydrocephalus, posterior fossa mass effect, and associated anomalies: • Macrocephaly or enlarging head circumference • Signs of raised intracranial pressure • Developmental delay • Cerebellar signs (truncal ataxia) • Cranial nerve abnormalities in severe cases • Symptoms from associated anomalies (spinal dysraphism, encephalocele, etc.) Q. What are the radiologic features of Dandy–Walker malformation? MRI/CT hallmark features: • Large posterior fossa • Upward displacement of tentorium • Cystic dilatation of the 4th ventricle • Hypoplastic or absent vermis • Elevation of torcula and transverse sinuses (from enlarged posterior fossa) • Hydrocephalus may be present Q. What is the management of Dandy–Walker malformation? Management focuses on treating hydrocephalus, decompressing the posterior fossa cyst when necessary, and addressing associated anomalies. Hydrocephalus is usually managed with a ventriculoperitoneal shunt placed in the lateral ventricle. If both the supratentorial ventricles and the posterior fossa cyst contribute to raised pressure or remain poorly communicating, a combined diversion system can be used in which ventricular and cyst catheters are connected via a Y-connector to a single distal shunt, allowing simultaneous and balanced drainage of both compartments. Posterior fossa cysts may also be managed with fenestration into adjacent cisterns or ventricular spaces when anatomically feasible. Associated lesions such as spinal dysraphism or occipital encephalocele are treated according to standard neurosurgical principles. Long-term care includes developmental assessment, physiotherapy, and surveillance for shunt function or cyst recurrence. Q. When specifically would you use a Y-connector in DWM? I will consider a Y-connector when: Hydrocephalus persists despite ventricular shunting because the posterior fossa cyst remains tense. Posterior fossa cyst drainage alone is insufficient, causing recurrent supratentorial hydrocephalus. Imaging shows two non-communicating or poorly communicating CSF compartments: • Dilated lateral/third ventricles • A large fourth-ventricular/posterior fossa cyst Endoscopic options (e.g., cyst fenestration, ETV) are either not feasible or have failed. In these situations, a combined cyst–ventricular shunt that merges both proximal catheters via a Y-connector into a single distal VP shunt maintains balanced drainage. Q. What are the advantages of a Y-connector shunt in DWM? • Single distal shunt path reduces infection risk compared to two separate shunts. • Equal decompression of both ventricles and cyst. • Minimizes compartmental pressure gradients that can cause cyst re-expansion. • Lower shunt hardware burden than dual, independent shunts. Q. What are the disadvantages / risks? • Potential for over-drainage of the posterior fossa compartment. • Flow competition between cyst and ventricles depending on catheter positioning. • Risk of shunt obstruction at the Y-junction. • Long-term dependency on a more complex shunt system. Q. What is the prognosis for DWM? Prognosis depends on: • Degree of vermian aplasia/hypoplasia • Severity of hydrocephalus • Presence of associated CNS anomalies (such as corpus callosum agenesis, encephalocele) Children with major associated anomalies or severe hydrocephalus often have poorer developmental outcomes. Q. What are the important differential diagnoses of DWM? Dandy–Walker variant Blake’s pouch cyst Retrocerebellar arachnoid cyst Mega cisterna magna Joubert syndrome

Intracranial Fungal Granuloma Q. What is an intracranial fungal granuloma? It is a localized chronic granulomatous infection of the brain or meninges caused by fungal organisms. The lesion forms due to a delayed hypersensitivity response with central necrosis and peripheral granulomatous reaction, often mimicking tuberculoma or neoplasm. It may involve brain parenchyma, meninges, or skull base, and is usually secondary to contiguous spread from paranasal sinuses. Q. What is its epidemiology and incidence? Intracranial fungal granulomas are more common in tropical and subtropical regions such as South and Southeast Asia. They typically occur in immunocompromised patients, i.e. those with diabetes mellitus, prolonged corticosteroid use, HIV/AIDS, malignancy, or chemotherapy. The most frequent organisms are Aspergillus species and Mucorales (Mucor, Rhizopus). CNS involvement is seen in about 10–20% of disseminated fungal infections. Rarely, fungal granulomas can occur in immunocompetent individuals, especially after chronic sinusitis. Q. What are the causative organisms and pathological features? A. Pathogenic fungi (can infect immunocompetent hosts): - Cryptococcus neoformans - Histoplasma capsulatum - Coccidioides immitis - Blastomyces dermatitidis - Paracoccidioides brasiliensis - Sporothrix schenckii B. Opportunistic fungi (in immunocompromised hosts): - Aspergillus fumigatus, A. flavus, A. niger - Mucorales: Mucor, Rhizopus, Absidia - Candida albicans - Phaeohyphomycosis (dematiaceous fungi) Histopathology: Granulomatous inflammation with central necrosis, epithelioid and giant cells, and fungal hyphae visible on PAS or GMS stain. Aspergillus shows acute-angle (45°), septate branching hyphae with angioinvasion and thrombosis. Mucor shows broad, non-septate right-angle branching hyphae. Angioinvasion leads to infarction, hemorrhage, and necrosis. Q. Which sites are commonly affected? - Frontal and temporal lobes by extension from paranasal sinuses (especially sphenoid and ethmoid). - Cavernous sinus, orbit, and skull base. - Cerebellum in hematogenous spread. - Basal cisterns and vascular structures are frequently invaded by Aspergillus. - Rhinocerebral mucormycosis often begins in nasal cavity and spreads via ethmoid sinuses into the orbit and frontal lobe. Q. What are the usual clinical features? - Persistent headache and vomiting due to raised intracranial pressure. - Focal deficits depending on site: hemiparesis, aphasia, cranial nerve palsy. - Seizures, altered sensorium, or proptosis in cases with orbital extension. - Cavernous sinus involvement causes ophthalmoplegia, ptosis, and facial numbness. - Often presents as a space-occupying lesion unresponsive to antibiotics or anti-tuberculous therapy. - Systemic features include fever, sinus discharge, or signs of chronic sinusitis. Q. What are the characteristic radiologic features? CT Scan: - Iso- to hyperdense lesion with irregular margins and surrounding edema. - May show calcifications or bone erosion in skull base involvement. - Variable ring or nodular enhancement after contrast. MRI: - T1: Iso- to hypointense core. - T2: Marked hypointensity due to iron and manganese within fungal elements. - Post-contrast: Peripheral or irregular ring enhancement. - DWI: May show restricted diffusion when abscess is present. - MR Spectroscopy: Lipid–lactate peaks with absent amino acid peaks (helps differentiate from pyogenic abscess). - Sinus disease and orbital or vascular invasion are often visible. T2 hypointensity with irregular ring enhancement is a characteristic feature of fungal granuloma. MR Angiography/CT Angiography: Essential to evaluate vascular encasement, arterial occlusion, or mycotic pseudoaneurysm formation (due to fungal angioinvasion). Q. What are the important differential diagnoses? - Tuberculoma - Pyogenic brain abscess - Neurocysticercosis (granular–nodular stage) - High-grade glioma or metastasis - Sarcoidosis or parasitic granuloma Q. How will you manage a case of intracranial fungal granuloma? A. Preoperative work-up: - MRI brain with contrast ± MR angiography - CT paranasal sinuses to identify the primary source - Nasal endoscopy for diagnostic biopsy - Routine hematologic tests and glycemic control - Fungal culture, KOH mount, and histopathologic confirmation via nasal biopsy if sinus involvement is present - Systemic Optimization: Urgent glycemic control (HbA1c/blood sugar), reversal of ketoacidosis, reduction of systemic steroids/immunosuppression, and baseline renal/hepatic profiling B. Surgical Management Indications: - Space-occupying lesion with mass effect. - Diagnostic uncertainty. - Failure of medical therapy or presence of abscess cavity. C. Surgical Goals: Achieve maximum safe resection and decompression. Obtain specimen for diagnosis. Control primary source if sinus or skull base involvement exists. D. Surgical Corridors: Anterior Skull Base / Cavernous Sinus: Frontotemporal, subfrontal, or cranio-orbitozygomatic (COZ) approach; or expanded endoscopic endonasal approach (EEA) for midline clival/sphenoid lesions. Posterior Fossa: Retrosigmoid or far-lateral approach depending on location. E. Operative Strategy & Pitfalls: Firm & Adherent Lesion: Granulomas are notoriously avascular/fibrotic center-wise but extremely adherent peripherally. Avoid Radical Capsule Traction: Fungi are highly angioinvasive. Encased major arteries (e.g., ICA, MCA, ACoA) become brittle and prone to intraoperative avulsion or postoperative stroke. Perform piecemeal internal debulking rather than en bloc resection when major vessels are involved. Irrigation: Copious irrigation with warm normal saline. Note: Intrathecal or local intraoperative Amphotericin B irrigation is controversial and generally avoided due to chemical arachnoiditis/neurotoxicity risks. Closure: Watertight dural repair (graft if needed) to prevent CSF leak and secondary bacterial meningitis. Postoperative Care: - Early initiation of systemic antifungal therapy. - Monitor renal and hepatic function regularly. - Control diabetes and immune suppression. Medical Therapy: General Principles: - Start systemic antifungal therapy immediately after diagnosis or biopsy. - Continue for at least 6–12 weeks or until complete clinical and radiological resolution. - Choose antifungal according to causative organism, site, and host immune status. 1. Aspergillosis (CNS Aspergilloma / Granuloma) - First-line drug: Voriconazole - Loading: 6 mg/kg IV every 12 h for 2 doses. - Maintenance: 4 mg/kg IV every 12 h or 200 mg PO q12 h. - Duration: Minimum 6–12 weeks (oral continuation up to 3–6 months). - Alternative: Liposomal Amphotericin B 3–5 mg/kg/day IV. - Resistant cases: Posaconazole 300 mg PO daily (after 300 mg BID on day 1) or Caspofungin 50 mg IV daily as adjunct. - Adjunctive therapy: Endoscopic sinus clearance if paranasal source present. 2. Mucormycosis (Rhinocerebral / Skull Base Form) - First-line: Liposomal Amphotericin B 5–10 mg/kg/day IV. - Conventional Amphotericin B deoxycholate 1 mg/kg/day if liposomal not available. - Step-down / maintenance: - Posaconazole 300 mg PO daily (after 300 mg BID day 1) - or Isavuconazole 200 mg IV/PO TDS for 48 h, then 200 mg daily. - Duration: At least 12 weeks; longer if sinus invasion persists. - Adjuncts: Surgical debridement of necrotic tissue, control of diabetes, cessation of steroids, and correction of acidosis. 3. Candida (Cerebral Candidiasis / Abscess) - First-line: Liposomal Amphotericin B 5 mg/kg/day IV ± Flucytosine 25 mg/kg q6 h PO. - Step-down: Fluconazole 400–800 mg/day PO or IV once improved. - Duration: 6–8 weeks minimum. Drain large or multiloculated abscesses surgically. 4. Cryptococcus (Cryptococcal Meningoencephalitis / Granuloma) - Induction (2 weeks): Amphotericin B 1 mg/kg/day + Flucytosine 25 mg/kg q6 h. - Consolidation: Fluconazole 400–800 mg/day PO for 8 weeks. - Maintenance: Fluconazole 200 mg/day PO for 6–12 months, especially in HIV-positive patients. - Adjunct: Manage raised ICP by CSF drainage if needed. 5. Dematiaceous (Phaeohyphomycosis and other rare fungi) - Voriconazole 200 mg PO q12 h or Posaconazole 300 mg PO daily preferred. - Duration: ≥ 6 months, often prolonged due to frequent relapse. Monitoring and Supportive Care: - Check renal and hepatic functions twice weekly during amphotericin therapy. - Maintain serum potassium > 3.5 mmol/L and magnesium > 1.8 mg/dL. - Avoid concomitant nephrotoxic drugs. - Monitor drug levels for voriconazole (trough 1–5 µg/mL). - Control underlying systemic disease (diabetes, immunosuppression). Q. What are the possible complications? - Postoperative hemorrhage or infarction from angioinvasion. - Meningitis or CSF leak. - Hydrocephalus. - Renal toxicity from amphotericin. - Recurrent infection from untreated sinus or orbital focus. Q. What is the prognosis? Mortality remains high, ranging from 25–40% in angioinvasive aspergillosis and mucormycosis. Favorable prognosis depends on: - Early diagnosis and prompt initiation of antifungal therapy. - Complete surgical excision where feasible. - Control of systemic risk factors. - Immunocompetent status of the patient. Q. What is the follow-up protocol? - MRI brain every 3 months during the first year, then every 6 months. - Monitor renal and hepatic parameters during therapy. - Repeat sinus evaluation to rule out recurrent infection. - Long-term oral antifungal prophylaxis in persistent immunocompromise. Recalls: - Most common agents: Aspergillus and Mucor. - Classic MRI finding: T2 hypointense core with irregular ring enhancement. - Confirm diagnosis by biopsy before starting therapy. - Voriconazole is the drug of choice for CNS aspergillosis. - Liposomal Amphotericin B (5–10 mg/kg/day) is preferred for mucormycosis. - Combined surgery and antifungal therapy give the best outcomes. - Early sinus debridement prevents recurrence and intracranial extension.

Get in Touch theneurosurgicalcaseroom@gmail.com Email Follow the Discourse Academic Inquiry Collaboration & Research We invite neurosurgeons, educators, and researchers to connect with our global academic network. Please share your interesting cases, research interests or collaboration requests below. First Name* Last Name* Institutional Affiliation* Email Address* Research Interest* Message* Submit Inquiry

Myelomeningocele A myelomeningocele is an open spinal dysraphism resulting from failed primary neurulation, where the neural placode lies on the surface without skin or bone covering. The spinal cord and meninges herniate through a posterior vertebral defect, exposing neural tissue to the external environment. It is the most severe form of spina bifida compatible with life. Q. How is myelomeningocele different from myeloschisis? In myelomeningocele, neural tissue protrudes and forms a placode attached to the skin edge, sometimes elevated above surrounding levels. In myeloschisis, there is no sac, and the open neural plate lies flush with the skin surface, representing the most severe form of non-closure. Q. What is the embryological basis of myelomeningocele? It results from failure of primary neurulation during the 3rd–4th week of gestation, leading to non-fusion of neural folds and continued exposure of neural ectoderm. Subsequent absence of dysjunction prevents mesenchymal migration, leading to failure of vertebral arches, muscle, and skin formation over the neural tube. The exposed placode then protrudes through the defect. Q. What is the epidemiology of myelomeningocele? Incidence ranges 0.5–1 per 1000 live births globally, higher in regions with nutritional deficiencies. Females are slightly more commonly affected. Folic acid deficiency, maternal hyperthermia, diabetes, and valproate exposure significantly increase risk. Recurrence risk in subsequent pregnancies is 2–3%. Q. What anatomical levels are most commonly affected? The lumbar region is most commonly involved, followed by lumbosacral, thoracic, and cervical regions. Higher-level lesions result in more severe neurological deficits. Q. What clinical features are seen at birth? Newborns present with a skinless sac containing neural placode and CSF. Neurological deficits correspond to lesion level: motor weakness or paralysis, sensory impairment, areflexia, neurogenic bladder and bowel dysfunction, and orthopedic deformities. Associated anomalies include Chiari II malformation, hydrocephalus, syringomyelia, and corpus callosum dysgenesis. Q. What skin findings help differentiate an open MMC from closed dysraphism? An open MMC always has no skin covering, exposed placode, and CSF leak. Closed dysraphisms are skin-covered and lack exposed neural tissue. Q. What are the common associated intracranial abnormalities? Chiari II malformation, hydrocephalus, aqueductal stenosis, corpus callosum agenesis/hypoplasia, brainstem kinking, small posterior fossa, ventriculomegaly, and syringomyelia. Q. How do you investigate a newborn with myelomeningocele? MRI spine after closure to assess associated tethered cord; MRI brain to assess Chiari II and hydrocephalus; head ultrasound if unstable; renal ultrasound; urodynamic studies; orthopedic assessment. Q. How is myelomeningocele diagnosed antenatally? Antenatal diagnosis is achieved through elevated maternal serum AFP, targeted obstetric ultrasound showing lemon sign, banana sign, ventriculomegaly, and spinal defect. Fetal MRI further delineates hindbrain herniation and lesion extent. Early diagnosis enables counseling, consideration of in utero repair, and planned delivery at specialized centers. Q. How will you counsel the mother of a child with MMC pre-operatively regarding management and expectations? I will explain that MMC requires early closure within 24–48 hours to prevent infection and protect neural tissue. Neurological deficits present at birth will not reverse and hydrocephalus evaluation and treatment may be required. Long-term risks include tethered cord, orthopedic deformities, and neurogenic bladder. I will outline a multidisciplinary plan involving neurosurgery, urology, orthopedics, and rehabilitation. I will also discuss risks of CSF leak, infection, wound issues, and the need for long-term follow-up. Q. How will you manage a newborn with myelomeningocele at birth? Sterile saline dressings, prone positioning, antibiotics, evaluation for hydrocephalus, and urgent closure within 24–48 hours. Q. When will you operate on myelomeningocele? Within 24–48 hours to prevent infection and neural injury and to allow early hydrocephalus management. In patients with Myelomeningocele (MMC), hydrocephalus is managed through a combination of clinical surveillance, surgical CSF diversion, and careful timing relative to the spinal closure. 1. Clinical & Radiological Evaluation Pre- and Post-Closure Surveillance: Monitor head circumference daily, assess fontanelles for fullness/bulging, evaluate the spinal wound for CSF leakage or tension, and observe for signs of raised ICP (irritability, vomiting, poor feeding, sunsetting eyes). Neuroimaging: Baseline cranial ultrasound or rapid-sequence MRI is performed to evaluate ventricular size, brainstem distortion (Chiari II malformation), and aqueductal stenosis. Post-spinal closure imaging is routinely repeated as hydrocephalus often manifests or worsens after MMC repair. 2. Timing of Hydrocephalus Treatment - Simultaneous vs. Staged Repair: Staged Repair (Most Common): MMC closure is performed first (within 24–48 hours of birth). The child is then monitored closely, and CSF diversion is performed only if overt signs of hydrocephalus or wound breakdown develop. Simultaneous Repair: Reserved for infants presenting with severe, obvious hydrocephalus (marked ventricular enlargement or high fontanelle tension) at birth to prevent high CSF pressure from causing spinal repair breakdown or CSF leakage. 3. Surgical Modalities Ventriculoperitoneal (VP) Shunt: Gold Standard / Primary Option: Historically and currently the most common treatment (~80% of MMC infants eventually require a VP shunt). Valve Selection: Programmable valves with anti-siphon devices are preferred to minimize complications over time. Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV/CPC): Alternative to Shunting: Combining ETV with CPC significantly improves success rates in infants under 6 months compared to ETV alone. Indication: Preferred in selected patients to avoid lifelong shunt dependency, particularly when aqueductal stenosis is present and the prepontine cistern is patent on imaging. 4. Associated Considerations (Chiari II & Wound Integrity) Chiari II Malformation: Hydrocephalus exacerbates hindbrain herniation. Decompressing the ventricles often improves Chiari II-related symptoms (stridor, vocal cord paralysis, apnea, or swallowing difficulties). Spinal Repair Protection: Untreated hydrocephalus increases back wound tension, leading to CSF fistula formation and a dramatically higher risk of meningitis. Controlling ventricular pressure directly protects the spinal closure site. Surgical Technique for MMC Closure: I will begin by positioning the newborn prone with the sac well protected on a sterile, moist dressing. I will pad the chest, pelvis, and extremities, ensuring no pressure is placed on the exposed neural placode. After wide antiseptic preparation, I will drape the entire back to allow free mobilization of soft tissues. I will first outline the incision. I will plan a fusiform elliptical incision around the base of the sac, incorporating dysplastic or epithelialized skin while preserving as much healthy skin as possible for closure. I will incise circumferentially through the epithelial–neural junction. As I deepen the incision, I will enter the sac if present and allow CSF to drain in a controlled fashion. Once the sac is opened, I will widely expose the underlying neural placode. At this point, I will use the operating microscope. I will carefully examine the placode to identify the true neural tissue and distinguish it from adherent membranes or epithelium. I will use sharp microsurgical dissection to separate the placode margins from the epithelialized skin. These adhesions may be delicate or fibrous, and I will free the neural edges circumferentially until the placode is completely mobilized from the surrounding tissues. If there is a transitional zone where skin or fibrous tissue blends with the placode, I will sharply define this interface to prevent tethering at closure. Once the placode is circumferentially free, I will begin the neural reconstruction. I will gently lift the lateral margins of the placode and identify the medullary folds. Using microforceps and fine sutures if needed, I will approximate these lateral neural folds toward the midline. My goal will be to re-tubularize the neural plate into a closed neural tube configuration. I will avoid traction, twisting, or compression on the neural tissue. If the placode is wide and cannot be completely tubularized, I will approximate it as much as safely possible to reduce its exposed surface and create a smooth contour under the dura. I will then focus on reconstructing the dura. I will identify the dysplastic dura around the margins of the bony defect. Using meticulous sharp and blunt dissection, I will separate the dura from underlying neural tissue, especially where it may be fused to the placode due to the congenital defect. This step requires careful attention to avoid injuring neural elements. I will extend the dissection laterally and inferiorly to mobilize the dura until I obtain edges that can be approximated without tension. If the dura is insufficient or too thin, I will harvest or place a dural substitute. I will perform a watertight dural closure using fine interrupted sutures, ensuring no gaps are left that could cause postoperative CSF leakage. I will ensure the reconstructed neural tube lies comfortably within the dural sac without compression or angulation. After completing the dural layer, I will address the muscle and fascial closure in multiple layers. I will mobilize the paraspinal muscles from their attachments along the defect, elevating them as needed to achieve a midline advancement. I will approximate the muscle and fascia layers over the dural repair in a tension-free manner to create robust, vascularized coverage. I will ensure no dead space remains that could predispose to CSF pooling or infection. I will reassess the remaining skin to ensure it can be closed without tension. If primary closure is possible, I will perform a layered closure with careful attention to preserving skin vascularity. For larger defects or tight margins, I will design rotational or advancement flaps to achieve a tension-free, well-perfused skin closure. I will verify that the final closure sits comfortably over the reconstructed dura and neural tube without tension points. Postoperatively, I will keep the infant prone and monitor closely for CSF leakage, wound breakdown, and hydrocephalus progression. I will initiate early evaluation by urology and orthopedics, and arrange follow-up imaging to assess the repair and guide decisions regarding shunt placement if hydrocephalus develops. Q. How will you close the myelomeningocele defect? I will try closing the defect in at least 5 layers. After re-tubularizing the neural placode, I will first achieve a watertight dural closure, either primarily or with a dural graft. The second layer is reconstruction of the lumbodorsal fascia or thoracolumbar fascia, which I will approximate over the dura when present. The third layer consists of paraspinal muscle advancement, where I will mobilize and bring the muscle bellies to the midline to provide vascularized coverage. The fourth layer is the subcutaneous tissue, which I will gently approximate without tension to eliminate dead space. The fifth and final layer is the skin, which I will close directly or with rotation/advancement flaps to ensure a tension-free, well-perfused final closure. Q. What are the perioperative complications during repair of myelomeningocele? Perioperative complications include injury to neural tissue during placode dissection, excessive bleeding from dysplastic dura or paraspinal muscles, temperature instability in the neonate, anesthetic difficulties including airway or ventilation issues in prone positioning, inadvertent CSF loss causing hemodynamic instability, difficulty achieving dural mobilization leading to incomplete watertight seal, vascular compromise of skin flaps, and placode torsion or kinking during re-tubularization. Intraoperative contamination of the exposed neural tissue or sac can increase risk of meningitis. Large defects may also predispose to venous bleeding from epidural plexus, and thoracic lesions may risk respiratory compromise. Some infants develop intraoperative apnea or bradycardia related to Chiari II brainstem dysfunction. Q. What postoperative complications may occur after MMC repair? Postoperative complications include CSF leak, pseudomeningocele, wound dehiscence, superficial or deep wound infection, and meningitis. Hydrocephalus may progress, requiring early VP shunt placement. Tethered cord can develop later due to scarring at the repair site. Skin flap necrosis may occur if closure was under tension. Shunt-related issues include infection, obstruction, or over-drainage. Respiratory dysfunction can worsen in infants with severe Chiari II, and urological deterioration may occur due to neurogenic bladder. Long-term complications include retethering, syringomyelia, and chronic pain. Q. What is the prognosis after MMC repair? Depends on lesion level, early closure, hydrocephalus control. High lumbar/thoracic lesions have poor ambulation; lower lesions may walk. Lifelong tethering risk persists. Renal preservation depends on early urological care. Cognitive outcome relates to hydrocephalus and brain anomalies. Q. What is the MOMS Trial and what were its key findings? The Management of Myelomeningocele Study (MOMS Trial) was a landmark randomized controlled trial comparing prenatal (in utero) repair of myelomeningocele with standard postnatal repair. It demonstrated that prenatal repair significantly reduced the need for ventriculoperitoneal shunting, improved hindbrain herniation associated with Chiari II malformation, and improved motor outcomes at 30 months of age. However, prenatal repair carried increased maternal risks including uterine dehiscence, preterm birth, and complications related to hysterotomy, limiting its applicability to highly selected centers and patients. Q. How will you counsel parents regarding the risk of recurrence in subsequent pregnancies? Recurrence risk is 2–3% after one affected pregnancy and around 10% after two affected pregnancies. High-dose folic acid (4 mg/day) one month pre-conception through the first trimester reduces recurrence by ~70%. Genetic counseling is recommended. Q. What are the recent advancements in management, including in utero surgery? Advancements include fetal surgery (open or fetoscopic) modeled after the MOMS Trial. Benefits include reduced hindbrain herniation and shunt dependence. Risks include maternal morbidity and preterm birth. Minimally invasive fetoscopic approaches are evolving, with improved perioperative fetal monitoring and neonatal support.

CVJ Anomalies 1. Occipital–Atlas (C0–C1) Anomalies Atlanto-occipital assimilation (occipitalization of atlas) Hypoplastic occipital condyles Asymmetrical occipital condyles Condylar hypogenesis or aplasia Third condyle (accessory occipital condyle) Proatlas segmentation defects 2. Atlas (C1) Anomalies Anterior arch cleft of C1 Posterior arch cleft of C1 Complete absence of the posterior arch of C1 Split atlas (bipartite atlas) Hypoplastic atlas Megalatlas (enlarged C1) Hypertrophied posterior arch Congenital C1 canal stenosis 3. Axis (C2) and Odontoid Anomalies Os odontoideum Ossiculum terminale persistens (persistent ossicle of the dens tip) Odontoid aplasia Odontoid hypoplasia Odontoid hypertrophy (rare) Retroflexed odontoid Fused odontoid–body synchondrosis (failure of normal fusion) Absent dens + anterior arch of C1 fusion (rare congenital block) Dens bifid (split odontoid) 4. Basilar/Clival Anomalies Basilar invagination Platybasia Short clivus (clival hypoplasia) Chiari-associated basilar settling Abnormal basal angle (primary cranial base deformity) 5. Atlantoaxial (C1–C2) Anomalies and Instability Congenital atlantoaxial instability Congenital C1–C2 facet malformation Congenital C1–C2 rotatory subluxation (rare congenital type) 6. Foramen Magnum Anomalies Congenital foramen magnum stenosis Narrow foramen magnum in skeletal dysplasias Enlarged foramen magnum (less common variant) 7. Ligamentous/Soft-tissue Anomalies Transverse ligament laxity (congenital) Alar ligament hypoplasia Apical ligament deficiency Congenital ligamentous laxity in syndromic disorders (Down, Morquio). These predispose to atlantoaxial instability. 8. Developmental Fusion Disorders (Beyond C1–C2) Klippel–Feil syndrome (congenital cervical fusions involving CVJ) Occipital–C1–C2 congenital block vertebra Multilevel congenital block vertebrae with CVJ compensation 10. Syndromic CVJ Anomalies These are congenital syndromes that characteristically involve CVJ abnormalities. Down syndrome: Odontoid hypoplasia, transverse ligament laxity, atlantoaxial instability. Morquio syndrome (MPS IV): Severe odontoid hypoplasia, ligamentous laxity, atlantoaxial instability. Achondroplasia: Foramen magnum stenosis, short clivus, brainstem compression. Osteogenesis imperfecta: Basilar invagination, platybasia. Cleidocranial dysostosis: Occipital condyle anomalies, atlanto-occipital instability. Goldenhar syndrome: Occipital condylar anomalies. Spondyloepiphyseal dysplasia: Odontoid hypoplasia, CVJ instability. Craniosynostosis syndromes (Crouzon, Pfeiffer): Platybasia, basilar invagination, Chiari I. Neurofibromatosis type 1 Dysplastic C1–C2 anomalies Q. How do congenital CVJ anomalies develop embryologically? Congenital CVJ anomalies arise from improper segmentation of the occipital somites, failure of chondrification or ossification of the proatlas and sclerotomes, or persistence of cartilaginous synchondroses. The occiput derives from the proatlas and four occipital somites, while the atlas and axis derive from the first and second cervical sclerotomes. Errors in these developmental steps result in occipitalization of the atlas, basilar invagination, odontoid anomalies such as os odontoideum and odontoid hypoplasia, and congenital fusions or clefts of the atlas arches. Associated abnormalities such as Chiari I malformation or syringomyelia occur when reduced posterior fossa volume or ventral brainstem compression alters CSF flow across the foramen magnum. Q. What are the major congenital anomalies of the CVJ? The major congenital anomalies include atlanto-occipital assimilation, basilar invagination, platybasia, os odontoideum, odontoid aplasia or hypoplasia, C1 arch defects, congenital atlantoaxial instability, and syndromic abnormalities such as those seen in Klippel–Feil syndrome, Down syndrome, Morquio disease, and other skeletal dysplasias. These anomalies cause pathology either by producing instability or by producing ventral or dorsal compression at the cervicomedullary junction. Q. What is atlanto-occipital assimilation? Atlanto-occipital assimilation is a failure of segmentation between the occiput and atlas that results in partial or complete bony fusion. This reduces the mobility of the atlanto-occipital joint and redistributes stress to the atlantoaxial joint, predisposing the patient to atlantoaxial instability. It frequently coexists with basilar invagination, Chiari I malformation, and vertebral artery anatomical variants. Patients develop headache, restricted neck motion, and progressive myelopathic symptoms if the canal diameter is reduced. Q. What is basilar invagination and how is it classified? Basilar invagination is the upward migration of the odontoid process into the foramen magnum, causing ventral compression of the medulla. It is most commonly congenital but may also be secondary to bone softening disorders. The odontoid lies above Chamberlain’s line or McGregor’s line and may project above the foramen magnum itself. Congenital basilar invagination is associated with assimilation of the atlas, platybasia, and often Chiari I malformation. Q. What is platybasia? Platybasia is an abnormal flattening of the skull base caused by dysgenesis of the clivus. It often coexists with basilar invagination and is recognized by an abnormally increased basal angle. Its significance lies in its association with ventral brainstem compression when combined with upward migration of the odontoid. Q. What is odontoid hypoplasia or aplasia? Odontoid hypoplasia refers to a short, underdeveloped dens, while aplasia refers to complete absence of the dens. These abnormalities impair the pivot function of the odontoid and predispose to gross atlantoaxial instability. They are common in skeletal dysplasias such as Morquio disease and in Down syndrome. Clinical manifestations include myelopathy, respiratory compromise, and episodes of transient quadriplegia. Q. What are congenital C1 arch defects? C1 arch defects arise from incomplete chondrification of the neural arches of the atlas. Posterior arch clefts or complete absence of the posterior arch may occur, and these can be misinterpreted as fractures if unrecognized. Although usually asymptomatic, some patients may develop myelopathy from posterior arch inward buckling or from associated instability. The vertebral artery may course anomalously through the defect, which is important during surgical instrumentation. Q. How do Chiari I malformation and CVJ anomalies relate? Chiari I malformation frequently coexists with basilar invagination, retroflexed odontoid, clival hypoplasia, and atlas assimilation. Reduced posterior fossa volume or ventral brainstem compression impairs CSF flow at the foramen magnum, resulting in tonsillar herniation and sometimes syringomyelia. In these patients, posterior fossa decompression may be insufficient if a significant ventral compressive component persists, necessitating atlantoaxial realignment or ventral decompression depending on reducibility. Q. What clinical features suggest congenital CVJ anomalies? Patients present with suboccipital or upper cervical pain, restricted neck movements, gait imbalance, long tract signs, hand clumsiness, spasticity, lower cranial nerve dysfunction, and in severe ventral compression, respiratory or swallowing difficulty. Drop attacks, syncope, or visual obscurations suggest vertebral artery compromise. Children may exhibit torticollis, developmental delay, or recurrent falls. Exacerbation of symptoms with flexion or extension suggests instability. Q. What imaging studies are required to evaluate these anomalies? Dynamic flexion and extension radiographs assess atlantoaxial instability. CT with sagittal and coronal reconstructions delineates bony anatomy, odontoid morphology, assimilation, platybasia, and the course of the vertebral arteries. MRI identifies cervicomedullary compression, tonsillar herniation, cord signal changes, and syringomyelia. Important measurements include the position of the odontoid relative to Chamberlain’s, McGregor’s, and McRae’s lines, the clivus-canal angle, and evaluation of reducibility on traction imaging. These measurements guide surgical planning, especially when choosing between posterior fusion and ventral decompression. Q. How do you manage congenital atlantoaxial instability? Management depends on symptoms and imaging findings. Symptomatic or radiographically significant instability requires surgical stabilization. Posterior C1–C2 fusion with instrumentation is the preferred approach. Distraction techniques may be used to realign the odontoid in reducible basilar invagination. Occipitocervical fusion is reserved for cases with atlanto-occipital assimilation, comminuted anomalies that preclude C1 fixation, or when alignment cannot be achieved at C1–C2 alone. Below is a concise list. A. C1–C2 Fusion Indications: AAI Os odontoideum Odontoid hypoplasia Reducible basilar invagination (Goel type A) Goel emphasizes C1–C2 distraction and fusion for reducible BI. B. Occipitocervical Fusion Indications: Irreducible AAI Occipital assimilation with instability Non-reducible BI Combined malformations affecting both OC–C1 and C1–C2 stability C. Ventral decompression (Transoral / Endoscopic endonasal odontoidectomy) Indications - Irreducible ventral compression by: Retroflexed dens Basilar invagination Severe platybasia Often followed by occipitocervical fusion. Q. When is ventral decompression indicated? Ventral decompression is indicated when irreducible ventral compression persists after maximal extension or traction. The common causes include a retroflexed odontoid, fixed basilar invagination, or severe platybasia. Transoral or endoscopic endonasal odontoidectomy is used to resect the offending dens, but posterior occipitocervical fusion is usually required afterward to maintain stability. Q. How are associated Chiari malformations addressed in the presence of CVJ anomalies? If ventral compression is significant, realignment or ventral decompression is performed first. Posterior fossa decompression is added when tonsillar herniation or syringomyelia persists after correction of the ventral pathology. In some cases of reducible basilar invagination, atlantoaxial distraction alone restores the CSF channels sufficiently to improve Chiari physiology without requiring posterior fossa decompression. Q. What complications may arise if congenital CVJ anomalies are untreated? Progressive cervicomedullary compression results in spastic quadriparesis, respiratory compromise, acute neurological deterioration from minor trauma, vertebral artery insufficiency, and sudden death. Chronic compression causes cord signal change, cranial nerve dysfunction, and irreversible neurological deficits. Instability may worsen with age, and minor neck movements may precipitate catastrophic neurological decline. Q. What factors determine prognosis after surgical correction of congenital CVJ anomalies? Prognosis depends on the degree and chronicity of medullary or spinal cord compression, the presence of syringomyelia, patient age, and the adequacy of decompression and stabilization. Early surgical intervention yields the best neurological recovery. Long-standing cord signal changes and severe ventral compression predict incomplete recovery. Proper alignment and robust fixation provide excellent long-term outcomes with low recurrence of symptoms.

Tethered Cord Syndrome Q. What is tethered cord syndrome? Tethered cord syndrome is a progressive neurological disorder caused by abnormal fixation of the spinal cord that restricts its normal movement and ascent within the spinal canal. Because the cord is anchored at an abnormally low point or attached to pathological tissue (lipoma, thick filum, adhesions, split cord septum), physiological stretching during growth leads to ischemia, metabolic stress, and neural injury, producing motor, sensory, orthopedic, and urological deterioration over time. It may occur in association with congenital dysraphic lesions or as an acquired postoperative condition after prior detethering. Q. What is the embryological basis of tethered cord syndrome? Tethered cord arises when there is abnormal interaction between neural and mesenchymal elements during neurulation. Disorders of primary neurulation (lipomyelomeningocele, dermal sinus), secondary neurulation (tight filum, terminal myelocystocele), or midline mesenchymal cleavage (split cord malformations) may leave persistent attachments that fix the distal cord. In postoperative tethered cord, scarring and adhesions after MMC or lipoma repair create tethering points along the reconstructed placode–dura interface. Q. What anatomical abnormalities cause tethering? Common tethering structures include: thick or fatty filum terminale, filar lipoma, lipomyelomeningocele / lipomyelocele, dermal sinus tract with intradural extension, split cord malformation septum (Type I), postoperative adhesions after MMC or lipoma surgery, terminal myelocystocele, retained placode adhesions, and epidermoid or dermoid tumors tethering the cord. The hallmark anatomical feature is a low-lying conus, typically below L2–L3, often with reduced movement on dynamic imaging. Q. What clinical features suggest tethered cord syndrome in childhood? Children typically present with progressive leg weakness, gait abnormalities, fatigability, or regression of previously achieved milestones. Orthopedic issues such as cavovarus foot, clubfoot, limb-length discrepancy, or progressive scoliosis are common. Sensory deficits may appear in the lower limbs. Urological symptoms frequently include urinary dribbling, delayed toilet training, recurrent UTIs, and enuresis. Cutaneous markers such as a tuft of hair, dermal sinus, lipoma, hemangioma, or asymmetric gluteal cleft are frequently present. Q. What are the common presenting signs and symptoms of tethered cord syndrome (with frequencies)? The most frequent presenting symptom is gait difficulty with lower extremity weakness (93%). Sensory deficits occur in 70%. Visible muscle atrophy, short limb, or ankle deformity occur in 63%. Cutaneous markers are present in 54% (hypertrichosis 22%, subcutaneous lipoma 15%, dermal sinus/hemangioma/multiple stigmata 17%). Bladder dysfunction is present in about 40%. Pain in the back, legs, or foot arches occurs in 37%. Scoliosis or kyphosis is present in 29%. Posterior spina bifida is present in 98%. Q. How does tethered cord syndrome present in adults? Adults typically present with progressive, activity-related neurological symptoms because the cord, already under chronic tension, becomes increasingly ischemic with posture, exertion, or minor trauma. The most common symptoms include lumbosacral or buttock pain that is worsened by flexion, sitting, prolonged standing, or Valsalva. Many adults have radicular pain in one or both legs. Motor symptoms include leg weakness, fatigability, and gait disturbance. Sensory symptoms include paresthesias or numbness. Urological symptoms such as urgency, frequency, incomplete emptying, stress incontinence, and overflow incontinence are common. Musculoskeletal findings include scoliosis or foot deformities from longstanding tethering. Symptoms may worsen after trauma, rapid weight gain, spinal stenosis, disc herniation, or pregnancy. Q. How does the presentation of adult tethered cord differ from childhood tethered cord? Children show progressive structural and developmental changes driven by growth, i.e. foot deformities, scoliosis, gait disturbance, regression of milestones, and continuous bladder dysfunction. Pain is uncommon in children. Adults, in contrast, present predominantly with pain, which could be perianal, perineal, bilateral, or shock-like, and with leg weakness rather than gait regression. Progressive scoliosis is uncommon in adults. Urological symptoms are prominent and include urgency, frequency, incomplete emptying, stress incontinence, and overflow incontinence. Cutaneous markers are present in fewer than half of adults. Adult symptoms are often precipitated by trauma, spinal degeneration, or maneuvers that stretch the conus. Q. What is the significance of scoliosis in tethered cord syndrome? Scoliosis is a sensitive indicator of tethering. In mild scoliosis (<10°), early detethering leads to neurological improvement in 68% and stabilization in the remaining 32%. In severe scoliosis (≥50°), outcomes are poorer, with 16% deteriorating even after untethering. Scoliosis progression often correlates with worsening tethering. Q. How do you diagnose tethered cord syndrome? Diagnosis is clinical, supported by imaging and urodynamics. MRI is the gold standard. It shows a low-lying conus (below L2–L3), thick or fatty filum (>2 mm), lipoma, split cord malformation, dermal sinus, or postoperative adhesions. MRI may also detect syringomyelia. Urodynamic testing is essential for assessing neurogenic bladder function. X-rays may reveal scoliosis or foot deformities. Cine MRI may demonstrate reduced cord movement. Q. What is the radiologic definition of a thickened filum terminale? A filum diameter greater than 2 mm is considered thickened. A normal filum measures less than 1 mm. A low conus supports tethering, but symptoms may also occur without a low conus if the cord is rendered taut by a tight filum. Q. What preoperative evaluations are recommended before detethering surgery? Preoperative cystometrogram (urodynamic testing) is strongly recommended even in apparently continent patients. MRI of the entire spine is required to define associated anomalies. Orthopedic evaluation for scoliosis and limb deformities, renal ultrasound in children with bladder symptoms, and careful neurologic baseline assessment are essential. Q. What are the indications for surgery in tethered cord syndrome? Surgery is indicated for neurological deterioration, urological decline, progressive orthopedic deformity, pain attributable to tethering, a tethering lesion with high-risk anatomy, and symptomatic tethering regardless of age. Early prophylactic surgery is often recommended in infants with clear lesions. Q. How will you perform detethering surgery? I will position the patient prone with careful padding and mark the midline. After antiseptic preparation and draping, I will make a midline incision and expose the posterior elements. I will perform a laminotomy or limited laminectomy over the conus–filum region. Under the operating microscope, I will open the dura longitudinally and tack it laterally for exposure. I will inspect for fat, a thick or tight filum, adhesions, lipomatous tissue, or split cord anomalies. If a thickened filum is present, I will identify it by its midline position, relative avascularity, and characteristic appearance, and confirm non-function with intraoperative stimulation. I will then safely coagulate and section the filum. If a lipoma is present, I will carefully debulk it using microsurgical technique, gently dissecting it from neural elements while preserving functional roots and the conus. In postoperative tethering, I will sharply release arachnoidal adhesions and free the neural tissue circumferentially. In SCM Type I, I will remove the bony or fibrous septum causing tethering. After complete detethering, I will expand the dural sac with a generous duraplasty using autologous or synthetic graft material to reduce the risk of retethering. I will close the dura in a watertight fashion and close the wound in multiple layers. Q. What are the perioperative complications of tethered cord surgery? Perioperative risks include neural injury causing new deficits, injury to nerve roots, epidural bleeding, CSF leak, incomplete detethering, intraoperative bradycardia or apnea during conus manipulation, and dural tears beyond the planned incision. Q. What postoperative complications may occur? These include CSF leak, pseudomeningocele, wound infection, meningitis, new neurological deficits, persistent bladder dysfunction, and the major long-term complication, retethering. Scoliosis or foot deformity progression may continue despite adequate release. Q. How will you counsel parents before tethered cord surgery? I will explain that tethered cord is a progressive disorder and surgery is intended to stop further neurological and urological decline. Improvement is most likely when symptoms are recent. Risks include CSF leak, infection, neurological worsening, and the possibility of retethering requiring future surgery. Long-term follow-up with neurosurgery, urology, and orthopedics is essential. Q. Are there any recent advancements in the management of tethered cord syndrome? Advancements include routine intraoperative neurophysiological monitoring, high-resolution MRI for detailing adhesions, cine MRI for assessing cord mobility, improved duraplasty materials to reduce scarring and retethering, and minimally invasive filum sectioning techniques. Q. What is the prognosis in tethered cord syndrome? Early intervention stabilizes neurologic and orthopedic status and may improve recent deficits. Bladder recovery is variable. Adults benefit most from pain relief. Retethering remains a lifelong risk, requiring continued monitoring.

Microsurgical Anatomy Sylvian Fissure Anatomy Part 1 | Surface Anatomy & Key Landmarks Simplified This video simplifies the surface anatomy and key anatomical landmarks of the Sylvian fissure into clear, structured concepts essential for both microsurgical orientation and viva preparation. Sylvian Fissure Anatomy Part 2 | Microsurgical Dissection & Surgical Landmarks Simplified This video takes the next step from basic anatomy into practical surgical understanding, highlighting how the Sylvian fissure is approached, opened, and utilized as a key corridor in neurosurgery. Temporal Lobe Anatomy | Structure, Boundaries & Functions | Part 1 Understand the temporal lobe anatomy in a clear and simplified way in this Part 1 video. This session breaks down the structure, boundaries, and key features of the temporal lobe using a visual and easy-to-follow approach. Temporal Lobe Anatomy | Part 2 Build on your understanding of temporal lobe anatomy in this Part 2 video. This session continues the simplified breakdown, focusing on deeper anatomical relationships and clinically relevant structures. Frontal Lobe Anatomy In this video, we simplify the anatomy of the frontal lobe, focusing on key gyri, functional regions, and their clinical and surgical relevance. Insular Anatomy In this video, we simplify the anatomy of the insula, one of the most important yet often overlooked regions of the brain. Located deep within the Sylvian fissure, the insular cortex plays a critical role in neurosurgical approaches, particularly in insula tumors, epilepsy surgery, and vascular procedures. Basal Ganglia Anatomy | Part 1 In this video, we simplify the anatomy of the basal ganglia and related deep brain structures that are fundamental to neurosurgery, neuroradiology, and clinical neurology. Basal Ganglia Anatomy | Part 2 | Lentiform Nucleus and Thalamus In Part 2 of this Basal Ganglia Anatomy series, we simplify the anatomy of the lentiform nucleus and thalamus, two deep brain structures that are essential for neurosurgery, neuroradiology, and clinical neuroanatomy. This video focuses on the anatomical relationships of the putamen, globus pallidus, internal capsule, and thalamus, with an emphasis on practical understanding and surgical relevance. Third Ventricle Anatomy Simplified | Surgical Anatomy & Boundaries Master the anatomy of the third ventricle with a neurosurgical perspective. Learn its boundaries, walls, roof, floor, hypothalamus, thalamus, foramen of Monro, aqueduct of Sylvius, surrounding neurovascular structures, and key surgical landmarks. Ideal for neurosurgery residents, medical students, neuroanatomy learners, and board exam preparation. Lateral Ventricle Anatomy | Part 1 | Ventricular System, Boundaries & Neuroanatomy In Part 1 of this Lateral Ventricle Anatomy series, we simplify the anatomy of the lateral ventricles using cadaveric specimens and practical surgical correlations. This video builds a strong anatomical foundation for understanding ventricular surgery and deep cerebral anatomy. Anatomy of Lateral Ventricles | Part 2 In part 2, we cover the boundaries and relations of the lateral ventricle, discussing each part separately and trying to build a clearer understanding of anatomical orientation.

Co-Founder Dr. Etizaz Ahmed MBBS, MS Neurosurgery Co-Founder, The Neurosurgical Case Room Consultant Neurosurgeon, Indus Medical College Hospital, Pakistan Creative & Strategic Director Dr. Quratulain Jamal Narejo MBBS, MRCEM Primary Creative & Strategic Director, The Neurosurgical Case Room Indus Hospital & Health Network, Pakistan

Coming Soon.

Neurofibromatosis Type 1, Type 2, and Schwannomatosis Q. What is Neurofibromatosis? Neurofibromatosis refers to a group of autosomal dominant neurocutaneous disorders characterized by the formation of nerve sheath tumors, skin pigmentation abnormalities, and systemic manifestations involving multiple organ systems. The three major recognized forms are Neurofibromatosis Type 1 (NF1), Neurofibromatosis Type 2 (NF2), and Schwannomatosis, all part of the neurofibromatosis-schwannomatosis spectrum. Neurofibromatosis Type 1 (NF1) Q. What is the genetic basis of NF1? NF1 results from mutations in the NF1 gene on chromosome 17q11.2, which encodes neurofibromin, a tumor suppressor protein that negatively regulates RAS signaling. Loss of neurofibromin leads to excessive RAS/MAPK pathway activation and uncontrolled Schwann cell proliferation. Q. What is the inheritance pattern? NF1 is autosomal dominant with variable expressivity and complete penetrance by adulthood. Around 50% of cases arise from de novo mutations. Q. What are the updated 2021 International Diagnostic Criteria for Neurofibromatosis Type 1 (NF1)? Diagnosis requires two or more of the following: 1. Six or more café-au-lait macules (>5 mm prepubertal, >15 mm postpubertal). 2. Two or more neurofibromas of any type, or one plexiform neurofibroma. 3. Axillary or inguinal freckling (Crowe sign). 4. Optic pathway glioma. 5. Two or more Lisch nodules (iris hamartomas), OR two or more choroidal abnormalities (bright patch lesions identified by near-infrared reflectance imaging / optical coherence tomography). 6. Distinctive osseous lesion such as sphenoid wing dysplasia, anterolateral bowing of the tibia, or pseudarthrosis of a long bone. 7. A heterozygous pathogenic NF1 gene variant with a variant allele fraction of 50% in normal tissue. 8. A parent who meets the diagnostic criteria for NF1 specified above. (Only a biological parent who officially meets the diagnostic criteria qualifies as a positive family history. Siblings and children no longer satisfy this criterion on their own, even if they have confirmed cases of NF1.) Q. What are the additional supportive (nonessential) features of NF1? Macrocephaly, short stature, and learning disabilities or ADHD. Seizures, developmental delay, or autism spectrum traits. Scoliosis, vertebral scalloping, long bone bowing, and tibial dysplasia. Vascular lesions (e.g., renal artery stenosis, moyamoya-like disease). Endocrine abnormalities, including precocious puberty (optic-hypothalamic glioma). Pheochromocytoma, GISTs, glomus tumors, and juvenile xanthogranulomas. Choroidal hamartomas visible on near-infrared OCT. Elephantiasis neuromatosa from plexiform neurofibroma overgrowth. Q. What are the clinical features of NF1? Cutaneous: café-au-lait macules, axillary/inguinal freckles, dermal and plexiform neurofibromas. Ophthalmic: Lisch nodules, optic pathway glioma. Neurologic: learning disability, ADHD, seizures, headaches. Skeletal: scoliosis, bone dysplasia. Tumors: MPNST, astrocytoma, pheochromocytoma. Q. What are the radiologic findings? MRI brain may show optic pathway glioma and T2 hyperintense white matter lesions (“unidentified bright objects”). Plexiform neurofibromas appear as T2 target sign lesions. Q. How is NF1 managed? Observation for asymptomatic lesions. Surgical excision for symptomatic or disfiguring neurofibromas. Optic gliomas: observe unless progressive visual loss. When treatment is required for progressive vision loss or imaging advancement, chemotherapy (e.g., carboplatin/vincristine or BRAF/MEK inhibitors) is first-line; radiation is strictly avoided due to the high risk of secondary malignancies and moyamoya syndrome. Screening: annual BP, ophthalmology, and neuro exam; MRI only if symptomatic. MPNST suspicion: rapid growth, pain, or heterogeneity on MRI → biopsy. Q. What is the prognosis? Most live normal lifespans; risk of malignant transformation (MPNST) and vascular complications determine prognosis. Neurofibromatosis Type 2 (NF2) Q. What is the genetic basis of NF2? NF2 is caused by mutations in the NF2 gene on chromosome 22q12, encoding merlin (schwannomin), a tumor suppressor that regulates cell–cell contact inhibition. Loss of merlin leads to Schwann cell overgrowth and meningeal proliferation. Q. What is the inheritance pattern? NF2 is autosomal dominant with variable expression and near-complete penetrance by age 60. Around 50% are de novo mutations, and one-third of those are mosaic. Q. What are the diagnostic criteria for NF2-related schwannomatosis (updated 2022)? Diagnosis can be made by: 1. Bilateral vestibular schwannomas, or 2. A first-degree relative with NF2-related schwannomatosis plus either - unilateral vestibular schwannoma, or - any two of: meningioma, schwannoma, glioma, neurofibroma, or juvenile cataract. 3. NF2 pathogenic variant in blood or tumor, with compatible clinical features. Q. What are supportive clinical features of NF2? Bilateral vestibular schwannomas (pathognomonic). Multiple meningiomas (intracranial and spinal). Spinal ependymomas and schwannomas. Ocular: posterior subcapsular cataract, epiretinal membranes, retinal hamartomas. Cutaneous: plaque-like or subcutaneous schwannomas (no café-au-lait spots). Cranial neuropathies and hearing loss as early symptoms. Family history of early-onset hearing loss or CNS tumors. Q. What is the typical age of presentation? Adolescence or early adulthood, though pediatric onset may occur in mosaic NF2. Q. What are the imaging findings? MRI Brain/IAC: bilateral vestibular schwannomas, multiple meningiomas. MRI spine: intradural extramedullary schwannomas, ependymomas, or meningiomas. Q. How is NF2 managed? MRI surveillance (brain and spine every 12–24 months). Microsurgery or radiosurgery for symptomatic tumors. Bevacizumab for progressive vestibular schwannomas to reduce growth and improve hearing. Rehabilitation with cochlear or brainstem implants for hearing loss. Genetic counseling for family. Q. What is the prognosis? Progressive and multisystemic; median life expectancy around 60 years. Morbidity arises from bilateral hearing loss and brainstem compression. Schwannomatosis Q. What is schwannomatosis? Schwannomatosis is a rare tumor predisposition syndrome characterized by multiple non-vestibular schwannomas without bilateral vestibular schwannomas. It is now considered part of the NF2-related schwannomatosis spectrum. Q. What is the genetic basis? Three defined molecular subtypes: 1. NF2-related schwannomatosis – NF2 gene mutation (chromosome 22q12). 2. SMARCB1-related schwannomatosis – SMARCB1 mutation (chromosome 22q11.23). 3. LZTR1-related schwannomatosis – LZTR1 mutation (chromosome 22q11.23). Tumorigenesis follows a four-hit, three-step model: biallelic loss of both NF2 and one modifier gene (SMARCB1 or LZTR1) in the same cell. Q. What is the inheritance pattern? Autosomal dominant with incomplete penetrance and variable expressivity. Many cases are sporadic. Q. What are the diagnostic criteria (2022 update)? Clinical diagnosis: - Two or more non-intradermal schwannomas confirmed histologically. - No bilateral vestibular schwannomas on MRI. - No constitutional NF2 mutation or first-degree relative with NF2. Molecular diagnosis: - Pathogenic variant in SMARCB1, LZTR1, or NF2, in germline or mosaic form, without bilateral vestibular involvement. Q. What are the clinical features? Chronic or paroxysmal pain (hallmark symptom). Palpable nerve masses along peripheral or spinal nerves. No vestibular or hearing symptoms. Minimal skin lesions, no café-au-lait spots or Lisch nodules. May have mononeuropathies or focal weakness due to nerve compression. Q. What are the radiological features? MRI: multiple enhancing schwannomas along peripheral or spinal nerves, no vestibular schwannomas. Diffusion and contrast help differentiate from meningiomas or neurofibromas. Q. What are the histopathological findings? Typical schwannoma pattern: - Antoni A and Antoni B areas. - Verocay bodies in Antoni A. - Strong S-100 positivity. - No entrapped axons (unlike neurofibroma). Q. What are the differences among genetic subtypes? SMARCB1-related: early onset, spinal schwannomas, occasional meningiomas. LZTR1-related: peripheral nerve tumors, occasional unilateral vestibular schwannoma. NF2-related: mosaic or milder NF2 phenotype. Q. How is schwannomatosis managed? Surgical resection of symptomatic schwannomas. Pain control with neuropathic agents and nerve blocks. MRI surveillance every 2–3 years. Genetic counseling for family. No established drug therapy; bevacizumab is ineffective except in NF2-related cases. Q. What is the prognosis? Excellent life expectancy; main morbidity is chronic neuropathic pain and recurrent surgeries. Histologic Discussion: Schwannoma vs Neurofibroma Q. How do schwannoma and neurofibroma differ? Schwannoma: encapsulated, eccentric to nerve, purely Schwann cells, Antoni A/B areas, Verocay bodies, strong S-100, no axons, enucleable, rare malignancy. Neurofibroma: unencapsulated, intraneural, mixed cell types with axons inside, patchy S-100, CD34 positive stroma, “shredded carrot” collagen, plexiform type has MPNST risk. Target sign on MRI typical for neurofibroma; heterogeneous appearance for schwannoma. Q. What are Antoni A and Antoni B areas, and Verocay bodies? Antoni A areas are hypercellular and organized with nuclear palisading. Antoni B areas are hypocellular, myxoid, and loosely arranged. Verocay bodies are rows of palisaded nuclei separated by acellular eosinophilic zones of Schwann cell processes, pathognomonic for schwannoma. Q. What is segmental or mosaic NF? A postzygotic mutation causing localized disease limited to one body segment; germline mosaicism can still transmit generalized NF to offspring. Q. What is plexiform neurofibroma and why is it significant? Pathognomonic of NF1, involving multiple fascicles (“bag of worms”). Carries 10–15% risk of malignant transformation to MPNST. Q. What is MPNST? A high-grade sarcoma arising from plexiform neurofibroma or peripheral nerve sheath, characterized by pain, rapid growth, and heterogeneous MRI appearance. Genetic mechanisms of tumorigenesis: Both NF1 and NF2 follow the two-hit tumor suppressor model; loss of both alleles (somatic and germline) causes tumor formation. NF1: RAS pathway dysregulation. NF2: loss of contact inhibition via merlin deficiency. Follow-up protocols: NF1 – annual BP, neuro and eye exams, MRI if symptomatic. NF2 – MRI brain/IAC annually, spine every 2–3 years, audiology yearly. Schwannomatosis – MRI every 2–3 years, pain and nerve function monitoring. Final recall summary: NF1 = Peripheral + Pigmentary. NF2 = Central + Vestibular. Schwannomatosis = Multiple Painful Schwannomas, No Vestibular Involvement.